Treatment of severe pulmonary hypertension: A bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy

Peptides

Volumn 26, Issue 8, 2005, Pages 1292-1300

  Taraseviciene Stewart, Laimute ^a   Scerbavicius, Robertas ^a   Stewart, John M ^b   Gera, Lajos ^b   Demura, Yoshiki ^a   Cool, Carlyne ^c   Kasper, Michael ^d   Voelkel, Norbert F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Apoptosis; Bradykinin agonist; Caveolin; Severe pulmonary hypertension

Indexed keywords

B 9972; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ RECEPTOR AGONIST; CASPASE 3; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; PROSTACYCLIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BLOOD VESSEL OCCLUSION; CAUSE OF DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVATION; FEMALE; HEART RIGHT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MALE; NONHUMAN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANIMALS; APOPTOSIS; BLOOD PRESSURE DETERMINATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; OLIGOPEPTIDES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 22544441298     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.03.050     Document Type: Conference Paper

References (40)

1. W.T. Abraham, M.V. Raynolds, B. Gottschall, D.B. Badesch, K.M. Wynne, and B.M. Groves Importance of angiotensin-converting enzyme in pulmonary hypertension Cardiology 86 Suppl 1 1995 9 15
2. S. Ameshima, H. Golpon, C.D. Cool, D. Chan, R.W. Vandivier, and S.J. Gardai Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth Circ Res 92 10 2003 1162 1169
3. A. Blaukat, P. Micke, I. Kalatskaya, A. Faussner, and W. Muller-Esterl Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure Am J Physiol Heart Circ Physiol 284 6 2003 H1909 H1916
4. C. Emanueli, and P. Madeddu Targeting kinin receptors for the treatment of tissue ischaemia Trends Pharmacol Sci 22 9 2001 478 484
5. C. Emanueli, M.B. Salis, J. Chao, L. Chao, J. Agata, and K.F. Lin Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice Arterioscler Thromb Vasc Biol 20 6 2000 1459 1466
6. A. Faussner, J.M. Bathon, and D. Proud Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation Immunopharmacology 45 1-3 1999 13 20
7. P. Groves, S. Kurz, H. Just, and H. Drexler Role of endogenous bradykinin in human coronary vasomotor control Circulation 92 12 1995 3424 3430
8. H. Heitsch Bradykinin B2 receptor as a potential therapeutic target Drug News Perspect 13 4 2000 213 225
9. H. Heitsch The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease Expert Opin Invest Drugs 12 5 2003 759 770
10. B. Hornig, and H. Drexler Endothelial function and bradykinin in humans Drugs 54 Suppl 5 1997 42 47
11. J. Howl, and S.J. Payne Bradykinin receptors as a therapeutic target Expert Opin Ther Targets 7 2 2003 277 285
12. Y. Ishigai, T. Mori, T. Ikeda, A. Fukuzawa, and T. Shibano Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes Am J Physiol 273 6 Pt 2 1997 H2659 H2663
13. K. Ishihara, M. Kamata, I. Hayashi, S. Yamashina, and M. Majima Roles of bradykinin in vascular permeability and angiogenesis in solid tumor Int Immunopharmacol 2 4 2002 499 509
14. K.K. Kang, G.J. Ahn, Y.S. Sohn, B.O. Ahn, and W.B. Kim DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats Arch Pharm Res 26 8 2003 612 619
15. M. Kitakaze, K. Node, T. Minamino, H. Asanuma, Y. Ueda, and H. Kosaka Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium J Mol Cell Cardiol 30 11 1998 2461 2466
16. A. Kuoppala, N. Shiota, J.O. Kokkonen, I. Liesmaa, K. Kostner, and M. Mayranpaa Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure J Am Coll Cardiol 40 1 2002 119 125
17. J. Liu, B. Razani, S. Tang, B.I. Terman, J.A. Ware, and M.P. Lisanti Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1 J Biol Chem 274 22 1999 15781 15785
18. J. Liu, X.B. Wang, D.S. Park, and M.P. Lisanti Caveolin-1 expression enhances endothelial capillary tubule formation J Biol Chem 277 12 2002 10661 10668
19. Y.H. Liu, X.P. Yang, V.G. Sharov, O. Nass, H.N. Sabbah, and E. Peterson Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors J Clin Invest 99 8 1997 1926 1935
20. B. Lorkowska, S. Chlopicki, E. Marcinkiewicz, and R.J. Gryglewski Statins rise cytoplasmic calcium level [Ca(2+)](i) in cultured endothelial cells Pol J Pharmacol 56 3 2004 313 318
21. B.S. McAllister, F. Leeb-Lundberg, and M.S. Olson Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts Am J Physiol 265 2 Pt 1993 C477 C484
22. S. Miura, Y. Matsuo, and K. Saku Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells Hypertension 41 5 2003 1118 1123
23. S. Miura, Y. Matsuo, and K. Saku Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling Atherosclerosis 175 2 2004 235 243
24. T. Nishimura, J.L. Faul, G.J. Berry, L.T. Vaszar, D. Qiu, and R.G. Pearl Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats Am J Respir Crit Care Med 166 10 2002 1403 1408
25. T. Nishimura, J.L. Faul, G.J. Berry, I. Veve, R.G. Pearl, and P.N. Kao 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats Am J Respir Crit Care Med 163 2 2001 498 502
26. S. Ono, and N.F. Voelkel PAF receptor blockade inhibits lung vascular changes in the rat monocrotaline model Lung 170 1 1992 31 40
27. D.S. Park, A.W. Cohen, P.G. Frank, B. Razani, H. Lee, and T.M. Williams Caveolin-1 null (-/-) mice show dramatic reductions in life span Biochemistry 42 51 2003 15124 15131
28. J.S. Silvestre, S. Bergaya, R. Tamarat, M. Duriez, C.M. Boulanger, and B.I. Levy Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway Circ Res 89 8 2001 678 683
29. J.M. Stewart, L. Gera, W. Hanson, J.S. Zuzack, M. Burkard, and R. McCullough A new generation of bradykinin antagonists Immunopharmacology 33 1-3 1996 51 60
30. J.B. Su, F. Barbe, R. Houel, T.T. Guyene, B. Crozatier, and L. Hittinger Preserved vasodilator effect of bradykinin in dogs with heart failure Circulation 98 25 1998 2911 2918
31. L. Taraseviciene-Stewart, L. Gera, P. Hirth, N.F. Voelkel, R.M. Tuder, and J.M. Stewart A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model Can J Physiol Pharmacol 80 4 2002 269 274
32. L. Taraseviciene-Stewart, Y. Kasahara, L. Alger, P. Hirth, M.G. Mc, and J. Waltenberger Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J 15 2 2001 427 438
33. D. Thuringer, L. Maulon, and C. Frelin Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells J Biol Chem 277 3 2002 2028 2032
34. R.M. Tuder, C.D. Cool, M. Yeager, L. Taraseviciene-Stewart, T.M. Bull, and N.F. Voelkel The pathobiology of pulmonary hypertension Endothelium Clin Chest Med 22 3 2001 405 418
35. K.K. Veeravalli, and A. Akula Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction Pharmacol Res 49 1 2004 23 29
36. R.C. Venema Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin Int Immunopharmacol 2 13-14 2002 1755 1762
37. N.F. Voelkel, and R.M. Tuder Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension Eur Respir J 8 12 1995 2129 2138
38. N.F. Voelkel, R.M. Tuder, J. Bridges, and W.P. Arend Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline Am J Respir Cell Mol Biol 11 6 1994 664 675
39. X.P. Yang, Y.H. Liu, G.M. Scicli, C.R. Webb, and O.A. Carretero Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats Hypertension 30 3 Pt 2 1997 735 740
40. X. Zhang, Y.W. Xie, A. Nasjletti, X. Xu, M.S. Wolin, and T.H. Hintze ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption Circulation 95 1 1997 176 182